Skip to content
Gavilimomab
Gavilimomab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target Basigin (Ok blood group).
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.81—11——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGAVILIMOMAB
INNgavilimomab
Description
Gavilimomab (mouse mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID244096-20-6
RxCUI—
ChEMBL IDCHEMBL2109193
ChEBI ID—
PubChem CID—
DrugBankDB06545
UNII IDTCR92293RC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BSG
BSG
Organism
Homo sapiens
Gene name
BSG
Gene synonyms
NCBI Gene ID
—
Protein name
Basigin (Ok blood group)
Protein synonyms
Uniprot ID
A0A087X2B5
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details